Breast Cancer News
In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
NEW YORK (Reuters Health) - Although fewer and fewer women have died of breast cancer each year over the past two decades, a new study suggests that improvements in survival have been slowest for the oldest women with the disease.
In a five-year review of 20 clinical trials, tamoxifen was shown to safely reduce both 15-year risk for recurrence and death in early-stage estrogen receptor-positive breast cancer.
CHICAGO (Reuters) - Women do not automatically have a higher risk of getting breast cancer just because someone else in the family has tested positive for breast cancer genes, U.S. researchers said Monday.
NEW YORK (Reuters Health) - An international survey of cancer doctors shows many question U.S. health advisers' 2010 rejection of Roche's drug Avastin to treat advanced breast cancer.
CHICAGO (Reuters) - More than half of healthy women who have an annual mammogram will get at least one false positive result over a 10-year period, and 7 to 9 percent will undergo a biopsy that doesn't turn out to show cancer, according to U.S. researchers.
NEW YORK (Reuters Health) - Breast cancer patients who take antioxidants may have an increased or decreased risk of death or recurrent cancer, depending on which vitamin they use, a new study suggests.
NEW YORK (Reuters Health) - Older women taking the breast cancer drug tamoxifen may have an increased risk of developing diabetes, a new study suggests.
NEW YORK (Reuters Health) - Starting breast cancer screening as early as age 25 may help women who carry a genetic mutation linked to a higher risk of cancer live longer, suggests a new study.
(Reuters) - Health insurer Blue Shield of California has decided not to pay for Roche Holding's drug Avastin to treat breast cancer after health advisers said it was not safe or clinically beneficial.
STOCKHOLM (Reuters) - Combining two drugs from Novartis and Pfizer to treat post-menopausal women with a certain type of advanced breast cancer more than doubled the time they lived without their disease getting worse, study data showed on Monday.